Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Campbell JE, Ussher JR, Mulvihill EE, et al
Overall prescribing rates for GLP-1 medications increased in September 2024 relative to June 2024 (+11.9%)
Dose adjustments of concurrent diabetes medications may be necessary
Common side effects from clinical trials The most frequently reported adverse events with retatrutide mirror those of other GLP-1 based medications
The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, followed by the synergistic combined effect of glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and glycemic control in those with the diseases of obesity and type 2 diabetes
Compounded medications cannot legally make efficacy claims because they have not undergone the clinical trials necessary to support such claims
US$ 24.52
US$ 21.36
US$ 28.26
US$ 21.74
US$ 21.92
US$ 29.84
US$ 28.53
US$ 29.69
US$ 23.80
